Last updated: February 20, 2026
What is NDC 69238-1596?
NDC 69238-1596 identifies Vimovo, a combination drug composed of naproxen and esomeprazole. Approved by the FDA, Vimovo is indicated for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It combines an NSAID (naproxen) with a proton pump inhibitor (esomeprazole) to reduce gastrointestinal side effects typical of NSAIDs.
Market Overview
Current Market Size
The global NSAID and gastroprotective drug markets collectively generate over $20 billion annually.[1] Vimovo’s segment, focused on osteoarthritis and rheumatoid arthritis, accounts for roughly $1.5 billion in U.S. sales as of 2022.[2] Its market penetrance remains steady but faces increasing competition from generic NSAID and PPI formulations.
Key Competitors
- Generic naproxen products: dominate NSAID space with aggressive pricing.
- Proton pump inhibitors (PPIs): available as generics, with omeprazole and lansoprazole leading.
- Combination drugs: other combination drugs with similar indications include Arthrotec (diclofenac/misoprostol).
Patent and Exclusivity Status
Vimovo's patent protection expired in 2018, leading to generic entry. The primary branded form now faces a generic landscape, which influences pricing, market share, and profitability.
Pricing Trends
Branded vs. Generic
- Branded Vimovo: traditionally sold at approximately $700–$900 per month (30-day supply).
- Generic naproxen + PPI combinations: priced around $20–$60 per month for the equivalent treatment.
Price Decline Post-Patent Loss
Following generics' entry in 2018, the average retail price of Vimovo declined by approximately 85%.[3] Sales volume increased by 25% in the succeeding two years, but net revenue margins decreased accordingly.
Market Trajectory & Forecast
Short-term Projections (2023–2025)
- The branded drug's sales will continue to decline, stabilized at $200–$300 million annually in the U.S.
- Generic competition will dominate, capturing 85–90% of the market share for this indication.
Long-term Outlook (2026–2030)
- The segment will shrink further as new therapies emerge.
- Potential growth if generic prices decline further, but overall revenue from Vimovo is expected to decrease by 60–75% from peak sales.
- Slight uptick possible if combination formulations evolve to include novel agents or if biosimilars disrupt existing competition.
Market Drivers
- Increased awareness of NSAID-related gastrointestinal risks.
- Shift towards cost-effective generic formulations.
- Prescribing patterns favoring single-entity drugs, reducing demand for combination drugs.
Regulatory and Policy Impact
- U.S. Patent Expiry (2018),[4] led to widespread generics.
- Affordable Care Act measures incentivize generic use.
- Future patent challenges or FDA approvals of alternative therapies could further impact market share.
Price Projections Summary Table
| Year |
Branded Vimovo (USD/month) |
Generic Total (USD/month) |
Market Share (Branded) |
| 2023 |
$300–$400 |
$20–$60 |
15–20% |
| 2025 |
$250–$350 |
$15–$50 |
10–15% |
| 2030 |
$150–$250 |
$10–$30 |
<5% |
Investment & R&D Implications
- Reduced profitability on Vimovo suggests limited R&D investment.
- Focus shifts toward novel NSAID, PPI, or combination therapies with improved safety profiles.
- Biosimilars or new formulations could reshape the competitive dynamics.
Key Takeaways
- Patent expiration in 2018 led to a sharp price decline for Vimovo.
- The market for this drug is highly competitive with generic NSAIDs and PPIs dominating.
- Long-term revenue prospects are limited; further declines in price and market share are expected.
- Innovation in therapeutic options for gastrointestinal protection and arthritis management will influence future demand.
FAQs
1. How high were Vimovo's sales before patent expiry?
Pre-expiry sales approached $900 million annually in the U.S..[2]
2. Are there any current patent protections or exclusivities?
Patents expired in 2018, leading to generic competition. No active exclusivity remains.
3. How do generics impact pricing?
Generics reduced the price of Vimovo by over 85%, making the branded product less attractive.
4. What factors could cause a price rebound?
Introduction of new formulations with better efficacy or safety profiles, or regulatory changes, could influence pricing, but current trends indicate continued decline.
5. Will Vimovo maintain any market niche?
Its use will be limited, primarily in patients needing gastrointestinal protection alongside NSAID therapy, but generic alternatives will likely dominate.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] EvaluatePharma. (2022). Global Sales Data for Rheumatology Drugs.
[3] GoodRx. (2023). Vimovo pricing history.
[4] U.S. Patent Office. (2018). Patent expiry notice for Vimovo.
Note: Market projections are based on current data; actual future prices may vary due to regulatory, competitive, or market developments.
